Vaseghi-Shanjani Maryam, Sharma Mehul, Yousefi Pariya, Samra Simran, Laverty Kaitlin U, Jolma Arttu, Razavi Rozita, Yang Ally H W, Albu Mihai, Golding Liam, Lee Anna F, Tan Ryan, Richmond Phillip A, Bosticardo Marita, Rayment Jonathan H, Yang Connie L, Hildebrand Kyla J, Brager Rae, Demos Michelle K, Lau Yu-Lung, Notarangelo Luigi D, Hughes Timothy R, Biggs Catherine M, Turvey Stuart E
Experimental Medicine Program, Faculty of Medicine, The University of British Columbia , Vancouver, Canada.
Department of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, Canada.
J Exp Med. 2025 Aug 4;222(8). doi: 10.1084/jem.20241174. Epub 2025 May 20.
ThPOK is a transcription factor that acts as a master regulator of CD4+ T cell lineage commitment. We report the first human disease caused by a genetic alteration in ThPOK, specifically, a damaging heterozygous de novo variant in ThPOK (NM_001256455.2:c.1080A>C, p.K360N). This patient exhibited the unusual constellation of persistent CD4+ T cell deficiency, allergy, interstitial lung disease, corneal vascularization and scarring, developmental delay, and growth failure. The ThPOKK360N variant displayed abnormal multimorphic activity, interfering with ThPOKWT (antimorph), failing to bind wild-type ThPOK consensus sequences (amorph), and showing novel DNA-binding specificity (neomorph). Single-cell RNA sequencing revealed defects in CD4+ and CD8+ T cell maturation and activation (hypomorph). Recapitulated in lentivirally transduced healthy control T cells and fibroblasts, the transcriptomic analysis showed ThPOKK360N-transduced T cells had impaired TCR activation and ThPOKK360N-transduced fibroblasts with increased profibrotic gene expression. This novel human disease confirms ThPOK's role in CD4+ T cell development but also uncovers novel roles in TCR activation and regulation of fibrotic pathways in fibroblasts.
ThPOK是一种转录因子,作为CD4+ T细胞谱系定向的主要调节因子。我们报告了首例由ThPOK基因改变引起的人类疾病,具体而言,是ThPOK基因中一种有害的杂合新生变体(NM_001256455.2:c.1080A>C,p.K360N)。该患者表现出持续的CD4+ T细胞缺陷、过敏、间质性肺病、角膜血管化和瘢痕形成、发育迟缓以及生长发育不良等异常症状组合。ThPOK K360N变体表现出异常的多态活性,干扰ThPOK野生型(反式显性负效应),无法结合野生型ThPOK共有序列(无效等位基因),并显示出新的DNA结合特异性(新等位基因)。单细胞RNA测序揭示了CD4+和CD8+ T细胞成熟和激活方面的缺陷(亚效等位基因)。在慢病毒转导的健康对照T细胞和成纤维细胞中重现该情况后,转录组分析显示,转导ThPOK K360N的T细胞的TCR激活受损,转导ThPOK K360N的成纤维细胞的促纤维化基因表达增加。这种新型人类疾病证实了ThPOK在CD4+ T细胞发育中的作用,但也揭示了其在TCR激活和成纤维细胞纤维化途径调节中的新作用。